GOING CONCERN AND MANAGEMENTS LIQUIDITY PLANS (Details Narrative) - USD ($) |
1 Months Ended | 6 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 06, 2025 |
Apr. 07, 2025 |
Mar. 07, 2025 |
Mar. 04, 2025 |
Oct. 14, 2024 |
Oct. 07, 2024 |
Jul. 11, 2024 |
Mar. 14, 2024 |
Mar. 08, 2024 |
Jan. 21, 2025 |
Dec. 31, 2024 |
Nov. 29, 2024 |
Aug. 23, 2024 |
Mar. 25, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Working capital deficit | $ (14,031,643) | |||||||||||||||
| Cash | $ 111,872 | |||||||||||||||
| Common stock price per share | $ 0.31 | $ 0.75 | $ 0.001 | $ 0.001 | ||||||||||||
| Lump sum payment of amortization | $ 275,000 | |||||||||||||||
| Net cash used in operating activities | $ (816,122) | $ (491,541) | ||||||||||||||
| Gross Proceeds | $ 847,700 | $ 235,396 | ||||||||||||||
| Conversion price | $ 0.40 | |||||||||||||||
| Exercise price of warrants maximum | 1.50 | |||||||||||||||
| Exercise price of warrants minimum | $ 1.00 | |||||||||||||||
| Debt conversion, description | $0.60 per share. In exchange for the modification, the Company issued 75,000 shares of restricted stock to the debt holder at $0.33 per share for a total value of $24,750. On December 31, 2024, the Company entered into a fourth amendment agreement to such promissory note. In accordance with the amendment, the parties agreed to modify the maturity date of the note from December 31, 2024 to February 28, 2025. In exchange for the modification, the Company issued 25,000 shares of restricted stock to the debt holder at $0.38 per share for a total value of $9,500 | |||||||||||||||
| Common stock shares issued | 500,000 | 104,500 | 30,000 | |||||||||||||
| Retention description | amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra | |||||||||||||||
| Common stock purchase | 500,000 | |||||||||||||||
| Exercise price | $ 1.00 | |||||||||||||||
| Proceeds from notes payable | $ 0 | $ 200,000 | ||||||||||||||
| Mr Lucido [Member] | ||||||||||||||||
| Common stock price per share | $ 0.41 | $ 0.34 | ||||||||||||||
| Promissory note outstanding | $ 725,000 | $ 200,000 | ||||||||||||||
| Common stock shares issued | 1,770,452 | 585,394 | ||||||||||||||
| Thomas Welch [Member] | ||||||||||||||||
| Common stock price per share | $ 0.39 | $ 0.31 | ||||||||||||||
| Common stock shares issued | 103,627 | 500,000 | ||||||||||||||
| Professional fees | $ 40,000 | |||||||||||||||
| Upfront purchase price | $ 400,000 | |||||||||||||||
| Retention description | amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra | |||||||||||||||
| Common stock purchase | 500,000 | |||||||||||||||
| Exercise price | $ 1.00 | |||||||||||||||
| Investors [Member] | ||||||||||||||||
| Common stock shares issued | 15,000 | 15,000 | ||||||||||||||
| Gross Proceeds | $ 15,000 | $ 13,350 | ||||||||||||||
| Exercise price | $ 1.00 | $ 0.89 | ||||||||||||||
| Unsecured Promissory Note Related Third Party [Member] | ||||||||||||||||
| Conversion price | $ 0.75 | 0.75 | $ 0.75 | $ 0.75 | $ 0.75 | |||||||||||
| Convertible conversion price decrease | 1.50 | 1.50 | 1.00 | 1.50 | 1.00 | |||||||||||
| Convertible conversion price increase | 2.00 | 2.00 | 1.50 | 2.00 | $ 1.50 | |||||||||||
| Debt instrument term | 9 months | |||||||||||||||
| Exercise price | $ 1.00 | $ 1.00 | $ 0.60 | $ 1.00 | $ 0.60 | |||||||||||
| Proceeds from notes payable | $ 200,000 | |||||||||||||||
| Restricted stock shares issued | 79,500 | 37,500 | 50,000 | 50,000 | 25,000 | 75,000 | 50,000 | 75,000 | ||||||||
| Interest rate | 8.00% | |||||||||||||||
| Restricted stock price per share | $ 0.35 | $ 0.30 | $ 0.52 | $ 0.52 | $ 0.38 | $ 0.30 | $ 0.30 | $ 0.33 | ||||||||
| Restricted stock value | $ 27,825 | $ 11,250 | $ 26,000 | $ 26,000 | $ 9,500 | $ 22,500 | $ 15,000 | $ 24,750 | ||||||||
| Debt instrument lum sum payment | $ 177,000 | $ 275,000 | $ 275,000 | |||||||||||||
| Debt instrument maturity start date | Sep. 06, 2024 | Aug. 10, 2024 | Sep. 08, 2024 | |||||||||||||
| Debt instrument maturity end date | Feb. 06, 2025 | Sep. 30, 2024 | Oct. 31, 2024 | |||||||||||||
| Amendment description | Company entered into a fifth amendment agreement to such promissory note. In accordance with the amendment, the parties agreed to modify the maturity date of the note from March 31, 2025 to March 31, 2026. The principal amount was increased from $275,000 to $330,000. Interest accrued at 5% per annum commencing on April 1, 2025 and the conversion price of the debt was adjusted to $0.34 per share | On February 28, 2025, the Company entered into a fourth amendment agreement to such promissory note. In accordance with the amendment, the parties agreed to modify the maturity date of the note from February 28, 2025 to February 28, 2026. The principal amount was increased from $275,000 to $330,000. Interest accrued at 5% per annum commencing on March 1, 2025. And the conversion price of the debt was adjusted to $0.33 | On February 28, 2025, the Company entered into a fifth amendment agreement to such promissory note. In accordance with the amendment, the parties agreed to modify the maturity date of the note from February 28, 2025 to February 28, 2026. The principal amount was increased from $275,000 to $330,000. Interest accrued at 5% per annum commencing on March 1, 2025. And the conversion price of the debt was adjusted to $0.33 | |||||||||||||
| February 22, 2024 [Member] | ||||||||||||||||
| Description of funding | The grant provides for (i) $4,131,123 in funding during the first year, (ii) $3,638,268 during the second-year, and (iii) $3,260,586 during the third-year subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds | |||||||||||||||
| Award granted by third party | $ 11,029,977 | |||||||||||||||